In mice, the deletion of the STOP protein leads to hyperdopaminergia and major behavioral -2 -
Introduction
In the past twenty years, a neurodevelopmental origin for schizophrenia has become the prevailing pathogenic hypothesis for the disorder (Harrison, 1999; Marenco and Weinberger, 2000) . Schizophrenia is regarded as a disease mainly expressed at the synapse level on the basis of both the hypothesis of a functional disconnection (Friston, 2002) and the data from genetic studies using DNA microarrays (Mirnics et al., 2001) . For a long time, the "dopaminergic hypothesis" of schizophrenia based on the hyperactivity of the dopaminergic system was the prevailing hypothesis for the disease. Indeed, it is well known that amphetamine and cocaine that release or inhibit the reuptake of dopamine, respectively, induce psychosis (Seeman, 1987) . However, a dysfunctioning of other neurotransmission systems has also been postulated and a more recent view includes disturbances also at the level of serotonin and glutamate neurotransmissions (Carlsson et al., 2001 ).
The "glutamatergic hypothesis" of schizophrenia comes from the observation that Nmethyl-D-aspartate (NMDA) glutamate-receptor antagonists, such as phencyclidine (Halberstadt, 1995) and ketamine (Lahti et al., 1995) have been shown to cause strong psychotomimetic effects with hallucinations and psychomotor signs. In contrast to dopaminergic agonists, which only mimic the positive symptoms of schizophrenia, NMDA antagonists produce the whole spectrum including negative and cognitive symptoms. The proposed mechanisms for a dysfunction of glutamatergic neurotransmission include interactions between the dopaminergic and glutamatergic systems (Carlsson et al., 2001) , excitotoxic neuronal damage in hippocampus and cortex (Deutsch et al., 2001 ) and alterations in glutamine and glutamate metabolism Eyolfsson et al., 2006; Kondziella et al., 2005) . It has been suggested that the dysregulation of dopamine transmission in schizophrenia may be secondary to alterations in glutamatergic NMDA receptor-mediated transmission (Carlsson et al., 2004; Olney and Farber, 1995) . Indeed, in healthy volunteers receiving ketamine, the amplitude of amphetamine-induced dopamine release was significantly enhanced compared to control conditions (Kegeles et al., 2000) . Thus, the elevated dopamine release seen in schizophrenic patients after amphetamine administration may well be secondary to a failure in glutamatergic control of dopamine neurons. This hypothesis is supported by experimental studies in rats (Miller and Abercrombie, 1996) .
Glutamate is the most important excitatory neurotransmitter in the mammalian brain. In the basal state, 60-75% of the total cortical glucose utilization corresponds to glutamatergic neuron activity, 10-15% reflect GABAergic neurotransmission and 10-15% glial needs (Lebon et al., 2002; Shulman et al., 2004; Sibson et al., 2001) . The synthesis of glutamate and GABA in neurons is closely connected to astrocytic metabolism and the homeostasis of glutamate is crucial to brain function for many reasons. Firstly, fast removal of glutamate from the synaptic cleft by astrocytes is necessary for short glutamate action on the postsynaptic target cell and thereby precise information signaling. Secondly, high extracellular concentration of glutamate is neurotoxic and excessive glutamate release may participate in the pathophysiology of many brain disorders, possibly involving schizophrenia (Deutsch et al., 2001) . Thirdly, since neurons lack the main anaplerotic enzyme in the brain, pyruvate carboxylase (Shank et al., 1985) , they depend on astrocytic supply of tricarboxylic acid (TCA) cycle intermediates because the constant loss of amino acid neurotransmitters from neurons would otherwise lead to restriction of neurotransmitter precursors (Sonnewald et al., 1993) . After being released from neurons, glutamate is cleared from the synapses by astrocytes, which transform glutamate to glutamine via glutamine synthetase which is an astrocyte specific enzyme (Norenberg and Martinez-Hernandez, 1979) . Astrocytes release glutamine into the extracellular space, from where it is taken up by neurons and converted back to glutamate and GABA or enters the TCA cycle via 2-oxoglutarate to provide carbon skeletons for the synthesis of other metabolites. This shuttling between astrocytes and neurons is called the "glutamine-glutamate cycle" (Berl and Clark, 1983 ).
An excellent tool to study metabolic pathways and glial-neuronal metabolic interactions C]glucose allows to study astrocytic and neuronal metabolism in the same animal (Taylor et al., 1996) . In the present work, this technique was applied to the characterization of neuronal and astrocytic metabolism in STOP (Stable Tubule only Polypeptide) protein knockout (KO) mice which have been proposed to be a "meaningful model for the study of the pathophysiology of schizophrenia" (Brun et al., 2005) . The STOP protein is a protein involved in the cold stability of microtubules, synaptic plasticity and neurotransmission (Andrieux et al., 2002) . The deletion of the STOP protein leads to a decrease in synaptic vesicle density in hippocampal CA1 terminals, impaired long term potentiation and depression at the level of Schaffer collaterals-CA1 pyramidal cell synapses. STOP KO mice are also characterized by disorganized activity with frequent shifts between hyperlocomotion and prostration, anxietyrelated behavior, inability to perform object recognition tasks and social withdrawal (Andrieux et al., 2002) . These mice also exhibit increased dopaminergic neurotransmission and increased efflux of dopamine in the nucleus accumbens upon stimulation (Brun et al., 2005) .
Taken together, these studies indicate the association between limbic hyper-dopaminergy and hippocampal hypo-glutamatergy in these mice (Andrieux et al., 2002; Brun et al., 2005) .
To study the cerebral metabolism of glutamate further, we explored the metabolic fate of [1- (Qu et al., 2000) , acetate is metabolized predominantly in astrocytes since it is selectively taken up into these cells (Waniewski and Martin, 1998) .
Materials and Methods

STOP KO male mice (STOP-/-), heterozygous (STOP+/-) and control WT littermates
(STOP+/+), 15 week-old, were generated as previously described (Andrieux et al., 2002) .
Mice were housed eight per cage and maintained in quiet, uncrowded facilities (room temperature of 22ºC ± 1°C) on a 12 hour light-dark schedule (7:00 a.m., lights on), humidity -5 -
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60%, and given unlimited access to lab chow and water. Males only were used for these experiments to eliminate confounding effects of variable estrogen level on neuronal excitability (Murphy et al., 1998) and [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate (504mg/kg, 0.6 M solution) followed by decapitation twenty minutes later. The heads were immediately frozen in liquid nitrogen and stored at -80ºC. Brains were removed from the slightly thawed skull, and because of their small size and limitations of sensitivity of the method, the forebrain/midbrain (cerebrum) including cerebral cortex and subcortical regions was used. The brainstem and cerebellum were discarded. The tissue was homogenized in 7% (w/v) perchloric acid and centrifuged at 4,000 g for 5 min. The procedure was repeated, the supernatants pooled and neutralized with 1 M KOH followed by lyophilization.
High Pressure Liquid Chromatography (HPLC)
Amino acids in cell extracts and medium were quantified by HPLC on a Hewlett Packard 1100 system (Agilent Technologies, Palo Alto, CA, USA). The amino acids were pre-column derivatized with o-phthaldialdehyde (Geddes and Wood, 1984) and subsequently separated on a ZORBAX SB-C18 (4.6 × 250 mm, 5 µm) column from Agilent using a phosphate buffer (50 mM, pH = 5.9) and a solution of methanol (98.75 %) and tetrahydrofurane (1.25 %) as eluents. The separated amino acids were detected with fluorescence and quantified by comparison to a standard curve derived from standard solutions of amino acids run after every twelve samples. C NMR spectra were obtained using a Bruker DRX-500 spectrometer after the samples had been re-dissolved in 300 μL D 2 O containing ethylene glycol 0.1% as an internal standard. Scans were accumulated with a 30º pulse angle and 25 kHz spectral width with 64K data points. The number of scans was 9000. The acquisition time was 1.308 s, the relaxation delay 0.5 s.
H NMR spectroscopy
A DRX-500 spectrometer was used to obtain 1 H NMR spectra with a sweep width of 8 kHz with 32K data points. The pulse angle was 90°, the acquisition time 2.045 s and the relaxation delay was 10 s. The number of scans was 250. Water suppression was set at the residual H 2 O resonance.
Labeling patterns
Most of the singlet peaks in the NMR spectrum ( Figure 1 ) represent label from [1-13 C]glucose. In contrast, the doublets seen in the spectrum are mostly derived from [1,2-13 C]acetate and thus astrocytic metabolism (Waniewski and Martin, 1998 C gives rise to the observed singlets in Figure 1 . Since both acetyl-CoA and oxalacetate can be labeled or unlabeled, the number of possible isotopomers of the TCA cycle derived metabolites is large and only compounds derived from the first and the second turns are presented in Figure 2 . Metabolic ratios were calculated but no differences were detected between groups (for details see Melø et al., 2006; .
Data analysis
The amounts of 13 C in the different metabolites were quantified from integrals of the relevant peaks obtained from NMR spectra with ethylene glycol as an internal standard. Factors for nuclear Overhauser and relaxation effects were applied to all spectra. Amounts of metabolites were quantified either from 1 H NMR spectra using ethylene glycol as internal standard and correcting for number of protons or by HPLC.
All results are given as means ± standard deviation. Statistics were performed using the two-tailed, unpaired Student's t-test; p <0.05 was considered significant.
Results
In the three genotypes, brain levels of all amino acids related to the TCA cycle and taurine, glutathione, succinate, lactate and NAD + were similar. The only difference was a significant (17%) decrease in the cerebral concentration of glutamine of STOP KO compared to WT mice (Table 1) .
Injection of [1- The pyruvate carboxylase/dehydrogenase (PC/PDH) ratios were calculated and no significant differences between the groups were detected (data not shown). Generally, carboxylation was low in all groups.
Discussion
The cytosolic step of neuronal glutamate and astrocytic glutamine metabolism were affected in the STOP KO mouse, whereas mitochondrial metabolism appeared unchanged. We propose that glutamine metabolism is decreased in major parts of the astrocytes of STOP KO mice, but unaltered in areas close to the presynapse and decreased in the vicinity of the postsynapse.
The STOP protein is a protein involved in the cold stability of microtubules, synaptic plasticity and neurotransmission (Andrieux et al., 2002) . Different isoforms of the STOP protein are expressed in neurons and astrocytes (Galiano et al., 2004) and it has been shown that in knockout mouse embryos, microtubule cold stability was lost in both neurons and glial cells while being partly preserved in heterozygous mice (Andrieux et al., 2002 ). This mouse model was used in the present study and a decreased level of glutamine was found in the cerebrum of homozygous KO compared to WT mice. The glutamine level in heterozygous mice was not significantly different from both wild type and knockout mice, indicating that reduced amounts of the STOP protein are sufficient for maintaining glutamine synthesis. As in STOP deficient mice, reduced amounts of glutamine were found in the left anterior cingulate cortex of patients with chronic schizophrenia in addition to reduction in glutamate (Theberge et al., 2003) . This decrease of glutamate and glutamine could possibly be an effect of long term treatment with neuroleptics, but the authors argue that this is unlikely and the present study supports this view. Two 1 H NMR spectroscopy studies of patients with never treated first episode schizophrenia, showed increased levels of glutamine in the medial prefrontal cortex and the left anterior cingulate cortex and thalamus, respectively (Bartha et al., 1997; Theberge et al., 2002) . Taken together, these reports indicate that first episode schizophrenic patients have an increased glutamine level in specific areas of the brain, whereas chronic patients have decreased levels of glutamate and glutamine. Thus, it appears that the 15-week-old STOP KO mice mimic chronic schizophrenia but not first episode schizophrenia, and hence STOP KO mice might be a good model for chronic schizophrenia.
In the present study, a significant decrease was found in the amount of [4,5 13 C]glutamine which is derived from [1,2-
13
C]acetate and therefore from astrocytic metabolism, indicating decreased glutamine synthesis in the STOP KO mice. A similar decrease was observed in the rat model of schizophrenia induced by the chronic injection of MK801 . Pyruvate carboxylation, another astrocyte specific pathway, was not changed compared to WT or heterozygous mice. It is conceivable that changes in microtubule stability will affect cytosolic enzymes such as glutamine synthetase (GS), whereas pyruvate carboxylase (PC), located on/in mitochondria was not affected. Other cytosolic enzymes, those related to glycolysis appeared unaffected, since the amounts of lactate and alanine were unchanged. The osmolyte taurine, the antioxidant glutathione and energy metabolism related NAD + were unchanged as well. As stated in the introduction, the astrocytes supply neurons with glutamine which can be converted to glutamate by the mitochondrial enzyme phosphate activated glutaminase (PAG). It is also important to note in this context that most of the glutamate in brain is located in glutamatergic neurons (Ottersen and Storm Mathisen 1986) . Since the amount of [4,5- The labeling (data not shown) and concentrations of the metabolites associated with primarily neuronal mitochondria, such as N-acetylaspartate, succinate and aspartate (Baslow, 2003; Palaiologos et al., 1988; Sonnewald et al., 1996) were similar in STOP KO, heterozygous and WT mice. A decrease was found in glutamate labeled from [1- stimulation has been reported previously by Brenner et al. (2005) . In that study, rats received a single injection of the NMDA receptor antagonist MK-801, a model for schizophrenia;
increased GS activity was postulated in astrocyte processes close to the postsynaptic neuron .
In conclusion, the results of the present study support previous indications that STOP KO mice have reduced synaptic glutamate release and are in a hypoglutamatergic state.
Hypoglutamatergia is thought to be an important causal mechanism of schizophrenia. STOP KO mice also show signs of hyperdopaminergia (Brun et al., 2005) . This, together with the reduction in glutamine levels, makes the STOP KO mouse a valid model of chronic schizophrenia and supports the hypothesis that dysregulation of dopamine in schizophrenia -12 -
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coexists with and may be secondary to alterations in glutamatergic NMDA receptor-mediated transmission (Carlsson et al., 2004; Olney and Farber, 1995) . 
Legends of figures
=glutamate, =NMDA receptors, =modulation of enzyme activity
